Companies › Q32 Bio
1 active drug program in 2 registered trials: 2 Phase 2; Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| bempikibart (ADX-914) IKZF3 degrader (molecular glue) | IKZF3 | Phase 2 | Atopic Dermatitis; Alopecia Areata | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05509023 | bempikibart (ADX-914) | Phase 2 | Atopic Dermatitis | Immunology | Dec 2024 |
| NCT06018428 | bempikibart (ADX-914) | Phase 2 | Alopecia Areata | Immunology | Jun 2026 |
Cash of $290m on 2026-09-30; operating cash outflow about $19m a year; runway about 187 months at that burn, to Apr 2042
Press releases filed as 8-K in the last year:
Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
AnaptysBio RAPT Therapeutics, Inc., a member of the GSK plc group of companies Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Zura Bio Chengdu Kangnuoxing Biopharma
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.